Investment Ratings
As per analysts rating in the last 6 months, the recommendation is to HOLD Parenteral Drugs
-
Master Rating:
-
Parenteral Drugs India has an operating revenue of Rs. 9.89 Cr. on a trailing 12-month basis. An annual revenue de-growth of -62% needs improvement, Pre-tax margin of -1270% needs improvement, NULL It is currently FORMING a base in its weekly chart and is trading around 7% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 23 which is a POOR score indicating inconsistency in earnings, a RS Rating of 49 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 147 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Parenteral Drugs (India) Ltd Forecast
Price Estimates
Eps And Sales Estimates
Parenteral Drugs (India) Ltd Synopsis
NSE-Medical-Diversified
Parenteral Drugs is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 12.17 Cr. and Equity Capital is Rs. 29.82 Cr. for the Year ended 31/03/2021. Parenteral Drugs (India) Ltd. is a Public Limited Listed company incorporated on 13/12/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC126481 and registration number is 126481.-
Market Cap
INR 12.82 Cr
-
Sales
INR 9.89 Cr
-
Shares in Float
0.81 Cr
-
No of Funds
6 K
-
Yield
%
-
Book Value
-0.02
-
U/D Vol Ratio
0.9
-
LTDebt/Equity
%
-
Alpha
0.86
-
Beta
0.42
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 73.28% | 73.28% | 73.28% |
| Mutual Funds | 0.01% | 0.01% | 0.01% |
| Financial Institutions/ Banks | 0% | 0% | 0% |
| Individual Investors | 21.98% | 21.89% | 21.96% |
| Others | 4.73% | 4.82% | 4.75% |
| Name | Designation |
|---|---|
| Mr. Manohar Lal Gupta | Chairman |
| Mr. Vinod Kumar Gupta | Managing Director & CFO |
| Mr. Govind Das Garg | Whole Time Director |
| Mr. Dharam Pal Khanna | Independent Director |
| Mr. Dilip Kumar Sinha | Independent Director |
| Mrs. Deepali Garhewal | Independent Director |
| Mr. Manish Verma | Independent Director |
| Mr. Anil Mittal | Non Executive Director |
Parenteral Drugs (India) Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 2.3503 | 2.9306 | 2.5699 | 2.0373 | 4.6414 |
| Operating Expenses Qtr Cr | 5.6192 | 5.5652 | -0.8221 | 4.9078 | 11.1076 |
| Operating Profit Qtr Cr | -3.2689 | -2.6346 | 3.392 | -2.8705 | -6.4662 |
| Depreciation Qtr Cr | 4.3311 | 4.3316 | 4.3171 | 4.3365 | 4.3365 |
| Interest Qtr Cr | 35.4654 | 34.0973 | 32.4601 | 32.0909 | 31.033 |
| Tax Qtr Cr | -9.4413 | -9.0161 | -8.5147 | -8.3117 | -8.1475 |
| Net Profit Qtr Cr | -33.6133 | -32.0366 | -24.8439 | -30.9746 | -33.6744 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 12.2313 | 32.12658 | 33.46313 | 34.29767 | 54.74216 |
| Operating Expenses Annual Cr | 23.9391 | 46.5584 | 49.6844 | 48.79391 | 86.76746 |
| Operating Profit Annual in Cr | -11.7716 | -14.68358 | -17.65651 | -15.84041 | -34.55767 |
| Depreciation Cr | 17.3265 | 17.34585 | 69.11933 | 18.56649 | 19.10094 |
| Interest Annual Cr | 125.4361 | 109.95567 | 96.0544 | 86.34005 | 73.93825 |
| Tax Annual Cr | -32.759 | -27.66342 | -33.49066 | -23.31048 | -11.07741 |
| Net Profit Annual Cr | -121.7114 | -114.06992 | -147.90434 | -96.09229 | -114.08707 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | 112.36516 | 455.78625 | 148.37982 | 120.98152 | |
| Cash from Investing Activity Annual Cr | 0.07893 | 0.09614 | -0.75083 | -0.2307 | |
| Cash from Financing Annual Activity Cr | -112.43114 | -455.79471 | -147.90504 | -120.63002 | |
| Net Cash Flow Annual Cr | 0.01295 | 0.08768 | -0.27605 | 0.1208 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | -683.2004 | -561.63081 | -447.24889 | -31.06309 | 63.22518 |
| Fixed Assets Annual Cr | 321.8141 | 339.14065 | 356.4865 | 616.92383 | 634.13228 |
| Total Non Current Assets Annual Cr | 499.4442 | 483.70065 | 472.5782 | 699.58092 | 692.905 |
| Total Current Assets Annual Cr | 67.3474 | 66.73874 | 66.57848 | 64.74525 | 66.9344 |
| Total Assets Annual Cr | 566.7916 | 550.43939 | 539.15668 | 764.32618 | 759.8394 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | -188.363 | -150.001 | -36.146 | -3.91 | |
| ROE Annual % | 0 | 0 | 0 | 0 | |
| ROCE Annual % | 6.98 | 25.21 | -14.19 | -13.08 | |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | -96.22 | -45.27 | -50.64 | -43.98 | -61.33 |
Parenteral Drugs (India) Ltd Technicals
EMA & SMA
CURRENT PRICE
4.3 
(0)
-
- Bullish Moving Averages 16
- Bearish Moving Averages 0
EMA
-
20 Day
3.63
-
50 Day
3.49
-
100 Day
3.39
-
200 Day
3.21
Parenteral Drugs (India) Ltd Resistance and support
4.3 PIVOT
-
First Resistance
4.3
-
Second Resistance
4.3
-
Third Resistance
4.3
-
First Support
4.3
-
Second Support
4.3
-
Third Support
4.3
-
RSI
75.41
-
MFI
100
-
MACD
0.23
-
MACD signal line
0.06
Parenteral Drugs (India) Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 2,060 | 206,000 | 100% |
| Week | 2,060 | 206,000 | 100% |
| 1 Month | 0 | 0 | % |
| 6 Month | 3,243 | 323,819 | 99.86% |
Parenteral Drugs (India) Ltd Price change analysis
0.35
Over 1 month
Low High 4.1 5.41
0.41
Over 3 month
Low High 2.5 5.41
-0.15
Over 6 months
Low High 2.5 5.41
1.7
Over Year
Low High 2.5 5.41Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| Glenmark Pharmaceuticals Ltd | 690.60 | 512.60 (-3.64%) | 119359 |
| Syngene International Ltd | 699.95 | 587.60 (-0.43%) | 53845 |
| Suven Life Sciences Ltd | 124.40 | 87.20 (-4.75%) | 79760 |
| Sequent Scientific Ltd | 336.40 | 150.60 (-3.71%) | 308328 |
News
PARENTERAL DRUGS (INDIA) LTD.-$ - 524689 - Announcement unde
Disclosure regarding publication of Unaudited Financial Results for the Quarter and half year ended on 30th September, 2021 in Newspaper Read More
Parenteral Drugs India Ltd - 524689 - Results-Financial Resu
Parenteral Drugs (India) Limited hereby submits Unaudited Financial Results on both Standalone and consolidated basis for the Quarter and ha Read More
PARENTERAL DRUGS (INDIA) LTD.-$ - 524689 - Board Meeting Out
Parenteral Drugs (India) Limited hereby submits Outcome of Board Meeting held on 12th November, 2021 Read More
Parenteral Drugs India Ltd - 524689 - Board Meeting Intimati
PARENTERAL DRUGS (INDIA) LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2021 ,inter a Read More
Parenteral Drugs India Ltd - 524689 - Shareholding for the P
Parenteral Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly C Read MoreBlogs